Agenus Inc., a leading immuno-oncology company, has announced an update to its virtual Stakeholder Briefing, which will take place on August 27, 2025, at 4:00 p.m. ET. The webcast will provide a strategic and financial overview of the company, as well as updates on its partnerships, clinical trials, and product pipeline. The program will feature speakers including Garo H. Armen, PhD, Founder, Chairman, and CEO of Agenus, and Richard M. Goldberg, MD, Chief Development Officer of Agenus.
The webcast will cover several key topics, including the company’s Zydus partnership, patient needs in colorectal cancer studies, recent clinical updates on its botensilimab and balstilimab programs, and an overview of the Phase 3 BATTMAN study in metastatic colorectal cancer. Additionally, there will be a spotlight on MiNK Therapeutics, a company in which Agenus has a significant stake.
Agenus is a leader in the development of immunological agents for the treatment of cancer. The company’s pipeline includes a range of antibody therapeutics, adoptive cell therapies, and adjuvants. Its lead product, botensilimab, is a multifunctional antibody designed to boost anti-tumor immune responses. Botensilimab has shown clinical responses in several metastatic cancers, and is being evaluated in combination with Agenus’ investigational PD-1 antibody, balstilimab.
The company has also developed balstilimab, a novel monoclonal antibody designed to block PD-1. Balstilimab has demonstrated clinical activity and a favorable tolerability profile in several tumor types. Agenus is headquartered in Lexington, MA, and has a global clinical operations footprint.
The webcast will conclude with a live Q&A session, and attendees can participate via a new virtual format. Pre-registration is not required, and the webcast link is available on the company’s website. Agenus cautions investors not to place undue reliance on forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from current expectations.